These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 7823611)

  • 1. If there is gold in the labeling index hills, are we digging in the right place?
    Aickin M
    J Cell Biochem Suppl; 1994; 19():91-3. PubMed ID: 7823611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate end-point biomarkers as measures of colon cancer risk and their use in cancer chemoprevention trials.
    Einspahr JG; Alberts DS; Gapstur SM; Bostick RM; Emerson SS; Gerner EW
    Cancer Epidemiol Biomarkers Prev; 1997 Jan; 6(1):37-48. PubMed ID: 8993796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of surrogate endpoint biomarkers for clinical trials of cancer chemopreventive agents: relationships to fundamental properties of preinvasive (intraepithelial) neoplasia.
    Boone CW; Kelloff GJ
    J Cell Biochem Suppl; 1994; 19():10-22. PubMed ID: 7823580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of proliferation indices as surrogate endpoint biomarkers.
    Alberts DS; Einspahr J; Aickin M; Hixson L; Earnest D; Roe D; Powell M
    J Cell Biochem Suppl; 1994; 19():76-83. PubMed ID: 7823609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker end-points in cancer chemoprevention trials.
    Boone CW; Kelloff GJ
    IARC Sci Publ; 1997; (142):273-80. PubMed ID: 9354926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer risk factors for selecting cohorts for large-scale chemoprevention trials.
    Greenwald P
    J Cell Biochem Suppl; 1996; 25():29-36. PubMed ID: 9027595
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Point: Surrogate end point biomarkers are likely to be limited in their usefulness in the development of cancer chemoprevention agents against sporadic cancers.
    Armstrong WB; Taylor TH; Meyskens FL
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):589-92. PubMed ID: 12869395
    [No Abstract]   [Full Text] [Related]  

  • 9. Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers.
    Kelloff GJ; O'Shaughnessy JA; Gordon GB; Hawk ET; Sigman CC
    Cancer Epidemiol Biomarkers Prev; 2003 Jul; 12(7):593-6. PubMed ID: 12869396
    [No Abstract]   [Full Text] [Related]  

  • 10. Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials.
    Kelloff GJ; Boone CW; Steele VE; Crowell JA; Lubet R; Sigman CC
    Cancer Res; 1994 Apr; 54(7 Suppl):2015s-2024s. PubMed ID: 8137331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostatic intraepithelial neoplasia (PIN) and other prostatic lesions as risk factors and surrogate endpoints for cancer chemoprevention trials.
    Bostwick DG; Aquilina JW
    J Cell Biochem Suppl; 1996; 25():156-64. PubMed ID: 9027613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surrogate end-point biomarker analysis in a retinol chemoprevention trial in current and former smokers with bronchial dysplasia.
    Lam S; Xu X; Parker-Klein H; Le Riche JC; Macaulay C; Guillaud M; Coldman A; Gazdar A; Lotan R
    Int J Oncol; 2003 Dec; 23(6):1607-13. PubMed ID: 14612933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoprevention trials in the cervix: design, feasibility, and recruitment.
    Mitchell MF; Hittelman WN; Lotan R; Nishioka K; Tortolero-Luna G; Richards-Kortum R; Hong WK
    J Cell Biochem Suppl; 1995; 23():104-12. PubMed ID: 8747384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
    Singletary SE; Atkinson EN; Hoque A; Sneige N; Sahin AA; Fritsche HA; Lotan R; Lu T; Hittelman WN; Bevers TB; Stelling CB; Lippman SM
    Clin Cancer Res; 2002 Sep; 8(9):2835-42. PubMed ID: 12231524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarkers and surrogacy: relevance to chemoprevention.
    Kensler TW; Davidson NE; Groopman JD; Muñoz A
    IARC Sci Publ; 2001; 154():27-47. PubMed ID: 11220666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surrogate end-point biomarkers in chemopreventive drug development.
    Kelloff GJ; Sigman CC; Hawk ET; Johnson KM; Crowell JA; Guyton KZ
    IARC Sci Publ; 2001; 154():13-26. PubMed ID: 11220652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer.
    Kelloff GJ; Sigman CC; Johnson KM; Boone CW; Greenwald P; Crowell JA; Hawk ET; Doody LA
    Cancer Epidemiol Biomarkers Prev; 2000 Feb; 9(2):127-37. PubMed ID: 10698472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chemoprevention of cancer. Prevention of cancer in groups with increased risk].
    Sanner T; Dybing E
    Tidsskr Nor Laegeforen; 1996 Aug; 116(19):2329-33. PubMed ID: 8804210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular chemoprevention by selenium: a genomic approach.
    El-Bayoumy K; Sinha R
    Mutat Res; 2005 Dec; 591(1-2):224-36. PubMed ID: 16099479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two simple approaches for validating a binary surrogate endpoint using data from multiple trials.
    Baker SG
    Stat Methods Med Res; 2008 Oct; 17(5):505-14. PubMed ID: 18285436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.